Abstracts

INCIDENT SYPHILIS INFECTIONS DECLINED IN WELL-CHARACTERIZED COHORT OF HIV+ PERSONS

Since 2000, syphilis rates have increased in the US; racial minorities are disproportionately represented. We used results of serially collected Non-Treponemal tests (NTrt) to examine incident syphilis infections in the US Military HIV Natural History Study (NHS), a cohort of HIV-infected Department of Defense beneficiaries We included all NHS subjects with visits since 2004.Syphilis was…

CLINICAL PERFORMANCE OF THE MP1P IMMUNOASSAY FOR RAPID DIAGNOSIS OF TALAROMYCOSIS

The gold standard to confirm Talaromyces marneffei infection (previously penicilliosis) is culture which can take up to 2 weeks. Diagnostic delay is associated with high mortality. Antigen detecting immunoassays offer rapid, specific and sensitive results, and have transformed management of other mycoses such as cryptococcosis. We describe the performance of the Mp1p immunoassay in a…

PREDICTING THE RISK OF DEATH IN HIV-ASSOCIATED TALAROMYCES MARNEFFEI INFECTION

Disseminated Talaromyces marneffei infection (formerly termed penicilliosis) is the third most common microbiologically confirmed opportunistic infection in Southeast Asia with mortality of up to 30% despite antifungal therapy. There are no clinical algorithms to predict treatment outcomes. We performed logistic regression and developed a simple risk prediction model for HIV-associated talaromycosis using data from a…

HOW WELL DO NEUROLOGIC SYMPTOMS IDENTIFY HIV-INFECTED INDIVIDUALS WITH NEUROSYPHILIS?

Current CDC guidelines recommend lumbar puncture in syphilis patients with signs or symptoms of neurologic disease. As part of a study of cerebrospinal fluid (CSF) abnormalities in syphilis, 410 HIV-infected individuals with untreated syphilis underwent lumbar puncture and a structured history that assessed the presence of new: headache, stiff neck, photophobia, vision loss, ocular inflammation,…

STOPPING SECONDARY TE PROPHYLAXIS IN SUPPRESSED PATIENTS WITH CD4 100-200 IS NOT SAFE

Current guidelines recommend that secondary Toxoplasma gondii prophylaxis can be safely discontinued in HIV-infected patients with suppressed viremia on antiretroviral therapy (ART) and a CD4 cell count >200 cells/mm3. Whether such a policy can be extended to patients with CD4 cell counts between 100-200 cells/mm3 is unknown. The Collaboration of Observational HIV Epidemiological Research in…